Please ensure Javascript is enabled for purposes of website accessibility

Why Pot Stocks Are Soaring Again in Tuesday's Stock Market

By Dan Caplinger - Feb 9, 2021 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news for the cannabis industry is standing out on a calm market day.

The stock market was narrowly mixed on Tuesday, pulling back from some of its recent gains. Investors are hopeful for further stimulus measures from the federal government, but they're uncertain about just how big they'll be or what groups will benefit the most. As of 11:30 a.m. EST, the Dow Jones Industrial Average (^DJI -1.72%) was down 47 points to 31,339. The S&P 500 (^GSPC -1.96%) had fallen 7 points to 3,909, but the Nasdaq Composite (^IXIC -2.61%) had inched higher by 15 points to 14,003.

However, the news from the marijuana stock sector was a lot more positive. There, shares of major players in the industry soared, with a number of factors helping to lift sentiment about cannabis investing.

Marijuana leaf displayed on a pile of leaves.

Image source: Getty Images.

On a high

Gains were widespread across the marijuana industry. Stalwart favorites saw good-sized rises in their share prices, including a 10% jump for Aurora Cannabis (ACB -6.78%) and an 11% rise for Canopy Growth (CGC -7.16%). Cronos Group (CRON -2.94%) lagged slightly behind with a 7% rise, but some other players in the group put up even stronger performances.

Leading the way higher was Tilray (TLRY), which jumped 34%. The Canadian company made an agreement with U.K.-based medicinal cannabis company Grow Pharma under which Grow will import Tilray-grown medical cannabis products for U.K. patients. Under the deal's terms, Tilray expects it will be able to get products across the Atlantic and into consumers' hands by March, with access by prescription either through private practitioners or from the U.K. National Health Service.

The move for Tilray follows up on good news from merger partner Aphria (APHA) on Monday. Aphria has given Chief Strategy Officer Denise Faltischek a dual role in leading Aphria's Germany division, with the goal of expanding international use. Aphria shares were up another 20% on Tuesday morning.

A brighter future

Interestingly, the good news in cannabis came despite a somewhat mixed earnings report from Canopy Growth. Fiscal third-quarter revenue grew 23% compared to year-earlier levels, but Canopy reported a massive net loss of 829 million Canadian dollars. Free cash flow was also negative.

However, Canopy is optimistic about its future. CFO Mike Lee noted that Canopy's cost-savings program is paying off for the company, and he expects the cannabis giant to reach profitability during fiscal 2022.

The other positive factor for the cannabis industry is the effort in Washington to decriminalize marijuana at the federal level. Investors have been hopeful ever since the final results of the recent presidential and Congressional elections became known that such measures would stand a better chance of moving forward. The potential for growth stemming from opening up the U.S. market is substantial, and although decriminalization wouldn't instantaneously mean that Americans in all 50 states would be able to buy cannabis products, it would remove a major impediment to the growing trend toward legalization in many jurisdictions.

Be careful out there

Of course, longtime marijuana investors will remember that this isn't the first time hopes for the future have caused a surge in cannabis stocks. Past rises gave way to precipitous declines. Yet with most stocks far below their levels from bull markets in past years, there's room for optimism right now without necessarily raising concerns about irrational exuberance in pot stocks.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$30,714.72 (-1.72%) $-538.41
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
$3,824.44 (-1.96%) $-76.35
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
$11,091.27 (-2.61%) $-297.22
Aurora Cannabis Stock Quote
Aurora Cannabis
$2.83 (-6.78%) $0.21
Canopy Growth Stock Quote
Canopy Growth
$5.45 (-7.16%) $0.42
Cronos Group Stock Quote
Cronos Group
$3.32 (-2.94%) $0.10
Aphria Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.